Mineralys Therapeutics, Inc. - Common Stock (MLYS)

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

Mineralys Therapeutics beat Q3 2025 EPS estimates. The biotech firm is advancing its lead drug, lorundrostat, toward a planned FDA submission.

Here's what needs to happen for these high flyers to continue soaring.

A new market leader has snuck into town over the past month as Small Caps have pushed to the top of the leader board. Whether the trend lasts, or not, will depend a lot on what the Fed does, but one thing is certain; after a year of tech-led mega caps setting new highs, investors have clearly shown an increased appetite for risk in the form of smaller, lesser known names.

Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people.

Wall Street is in full rally mode after July’s inflation data eased fears that tariff-related cost pressures were widespread. The headline Consumer Price Index (CPI) came in below expectations, holding steady at 2.7% year-over-year and fueling speculation of upcoming interest rate cuts.

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable safety results.